Olanzapine in Anorexia Cachexia Syndrome Among Advanced Cancer Patients
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
164 patients will be recruited..Adult patients diagnosed with incurable solid tumors and CCAA
who presented to Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine (NEMROCK) -
Kasr Al-Ainy School of Medicine - Cairo University will be randomly distributed into 1:1..82
will receive Olanzapine 5 mg daily at night and 82 patients will receive placebo for 4 weeks.
Primary outcome is Change in loss of appetite score from day 0 to day 7 of treatment and
secondary outcomes change in body weight, change in loss of appetite score..and change in
quality of life